BridgeBio have significantly improved this progress of a novel treatment for cardiac amyloidosis, utilizing Attruby. Initial trial data suggests potential benefits for those diagnosed with a severe disease. This focus underscores BridgeBio's dedication to managing unmet healthcare needs in a cardiology field. Attruby: BridgeBio's Novel Approach to